United States: FDA Addresses Compounding Of Animal Drugs From Bulk Drug Substances

The U.S. Food and Drug Administration (FDA) has released a Notice of Draft Guidance and Withdrawal of Compliance Policy Guidance (Guidance Notice), along with a Draft Guidance for Industry (Draft Guidance) addressing compounding of animal drugs from bulk drug substances. A separate Notice announced that FDA is soliciting nominations for the Bulk Drug Substance List (Bulk List Notice) for use in the compounding of animal drug products. In the wake of FDA's publication of a number of guidance documents relating to the implementation of Section 503A and 503B of the Drug Quality and Security Act (DQSA), which is only applicable to the compounding of human drugs, there remained outstanding questions as to the status of compounded animal drugs. Through this Draft Guidance, FDA is trying to provide some clarity on the remaining animal compounding issues. Comments and nominations are due by August 17, 2015.

Guidance Notice

The Guidance Notice indicates that the Draft Guidance provides information on the application of the Federal Food, Drug, and Cosmetic Act (FFDCA) to compounded animal drug products. Specifically, the Guidance Notice clarifies that sections 503A and 503B of the FFDCA do not apply to animal drugs and that, while there are exemptions for compounding from FDA approved products, FDA makes no distinction between the compounding of animal drug products from bulk substances and the manufacturing or processing of other animal drug products. Thus, the same requirements that apply to manufactured animal drugs also apply to compounded animal drugs, with the limited statutory exception provided in FFDCA sections 512(a)(4) and (a)(5) which allows for extra-label use of a compounded animal drug made from already-approved animal or human drugs. The extra-label use is exempt from FDA approval requirements and adequate directions for use if the product complies with 21 C.F.R. Part 530, which addresses extra-label use in animals of approved animal and human drugs. The Guidance Notice specifies that the Draft Guidance does not address extra-label use or repackaging of approved animal drugs. However, FDA is soliciting responses to specific questions posed in the Guidance Notice, including, but not limited to:

  • Is additional guidance needed to address the repackaging of drugs for animal use?
  • Is additional guidance needed to address the compounding of animal drugs from approved animal or human drugs under sections 512(a)(4) or (a)(5) of the FFDCA and 21 CFR Part 530?
  • Is additional guidance needed to address the compounding of animal drugs from bulk drug substances for food-producing animals?
  • Do United States Pharmacopeia and National Formulary (USP–NF) chapters <795> and <797> provide suitable standards for animal drugs compounded by veterinarians, and if not, what standards of safety, purity, and quality should apply to animal drugs compounded by veterinarians?
  • Should licensed veterinarians be able to sell or transfer an animal drug compounded from bulk drug substances by a state-licensed pharmacy or an outsourcing facility to owners or caretakers of animals under the veterinarian's care?
  • Should the final guidance include a condition on the amount or percentage of compounded animal drugs that a state-licensed pharmacy or outsourcing facility can ship in interstate commerce? If so, what would a reasonable amount be?

The Guidance Notice also announces the withdrawal of FDA Compliance Policy Guide (CPG) Section 608.400 which was issued in 2003. FDA is withdrawing this CPG because it "is no longer consistent with FDA's current thinking on the issue it addresses" because "it does not focus on the three main concerns FDA has about animal drug compounding." (Guidance Notice at 28624, 28625). These concerns include: (1) using bulk drug substances to compound copies of approved animal or human drugs, (2) compounding from bulk drug substances for food producing animals, and (3) compounding office stock from bulk drug substances. Because the issuance of the Draft Guidance and the withdrawal of the CPG may lead to enforcement confusion among stakeholders, FDA has indicated that until the Draft Guidance is finalized, it will "look at the totality of the circumstances when determining whether to take enforcement action for unlawful animal drug compounding activities." (Id.).

Draft Guidance

The Draft Guidance addresses compounding of animal drugs from bulk drug substances that do not fall within the limited extra-label use exception, as FDA is concerned that the "unrestricted compounding of animal drugs from bulk drug substances has the potential to compromise food safety, place animals or humans at undue risk from unsafe or ineffective treatment, and undermine the incentives to develop and submit new animal drug applications." (Draft Guidance at 3). FDA does not plan to take enforcement action if a state-licensed pharmacy, licensed veterinarian, or outsourcing facility uses bulk drug substances to compound animal drugs in accordance with the conditions set out in the Draft Guidance.

For example, if an animal drug is compounded by an outsourcing facility, to satisfy the requirements spelled out in the Draft Guidance the compounded drug must:

  1. Be compounded only from bulk drug substances appearing on Appendix A of the Draft Guidance, for which FDA is currently soliciting nominations;
  2. Be compounded by or under the direct supervision of a licensed pharmacist;
  3. Not be intended for use in food-producing animals;
  4. Be compounded in accordance with current good manufacturing practices requirements;
  5. Be compounded with bulk drug substances manufactured by an establishment that is registered under section 510 of the FFDCA (21 U.S.C. § 360) and is accompanied by a valid certificate of analysis;
  6. Not be sold or transferred by an entity other than the outsourcing facility that compounded such drug;
  7. Comply with the adverse event reporting requirements, i.e., within 15 days of becoming aware of any product defect or serious adverse event associated with animal drugs it compounded from bulk drug substances, the outsourcing facility reports it to FDA, on Form FDA1932a;
  8. Be included, along with all other drugs compounded for animals by an outsourcing facility, on the report required by section 503B of the FFDCA to be submitted to FDA each June and December identifying the drugs made by the outsourcing facility during the previous six-month period;
  9. Be accompanied by a prescription or order that states the drug is intended to treat the species and condition(s) for which the substance is listed in Appendix A; and
  10. Be labeled in accordance with the Draft Guidance.

Bulk List Notice

The Bulk List Notice explains the nomination process for bulk drug substances to be included in the Draft Guidance Appendix A and is applicable only to animal drug compounding conducted by outsourcing facilities using bulk drug substances. FDA intends to review nominations for the initial version of the list based on the responses submitted to the Bulk List Notice, but will then review nominations on a rolling basis and periodically update Appendix A.

A bulk drug substance will be included in Appendix A only when the following criteria are met:

  1. There is no marketed approved, conditionally approved, or index-listed animal drug that can be used as labeled to treat the condition;
  2. There is no marketed approved animal or human drug that could be used under sections 512(a)(4) or (a)(5) of the FFDCA and 21 CFR Part 530 to treat the condition;
  3. The drug cannot be compounded from an approved animal or human drug;
  4. Immediate treatment with the compounded drug is necessary to avoid animal suffering or death; and
  5. FDA has not identified a significant safety concern specific to the use of the bulk drug substance to compound animal drugs (under the listed conditions and limitations).

FDA notes that inactive ingredients are not required to appear in Appendix A to be used in compounding animal drug products.

Comments on the Draft Guidance and nominations for the Bulk Drug Substance List are due by August 17, 2015, and can be submitted electronically to http://www.regulations.gov.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions